Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...
AND THERE WAS ONLY ONE TRAIL THAT IS OPEN AND OPERATING FOR PEOPLE. IT’S NOT YET GROOMED, SO IT’S GOING TO FEEL A BIT BUMPIER THAN USUAL. BUT THERE’S STILL PLENTY OF SNOW HERE FOR PEOPLE TO ENJOY HERE ...
These strong risk-adjusted results have not resulted in a bumpier ride for investors. This strategy took on similar risk as the benchmark, as measured by standard deviation. Finally, the share ...